MedTrace Logo

Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

NCT06961617 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-05-08

No results posted yet for this study

Summary

This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.

Conditions

Interventions

DRUG

LioCyx-M, HBV antigen-specific TCR-redirected T cells

Via intravenous (IV) infusion

Sponsors & Collaborators

  • Beijing GoBroad Hospital

    collaborator OTHER

  • Lion TCR Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Tina Wang · Lion TCR Pte. Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2027-12-01
Completion
2028-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06961617 on ClinicalTrials.gov